Gene
JAK2
JAK2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (23), Actionable biomarkers (6), Trial mentions (182), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention JAK2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 35 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 19 of 8,738 | 0.22% | not measured | |
| 2025 | 7 of 8,875 | 0.08% | not measured | |
| 2024 | 8 of 8,597 | 0.09% | not measured | |
| 2023 | 8 of 8,275 | 0.10% | 83 of 11,460 | 0.72% |
| 2022 | 6 of 8,285 | 0.07% | 107 of 13,598 | 0.79% |
| 2021 | 11 of 8,692 | 0.13% | 136 of 15,045 | 0.90% |
| 2020 | 13 of 7,640 | 0.17% | 115 of 14,459 | 0.80% |
| 2019 | 16 of 7,300 | 0.22% | 102 of 12,159 | 0.84% |
| 2018 | 8 of 6,927 | 0.12% | 99 of 11,854 | 0.84% |
| 2017 | 13 of 6,558 | 0.20% | 98 of 11,595 | 0.85% |
Showing 10 of 37 years.
Assay-provider ledger (23)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Center for Personalized Diagnostics, Biodesign Institute, Arizona State University | Not a company | Analytical validation | 1 | November 01, 2017 |
| Mayo Clinic | Not a company | Analytical validation | 1 | November 01, 2017 |
| Merck Research Laboratories | Pharma or other | Analytical validation | 1 | November 01, 2017 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 5 | May 19, 2017 |
| Memorial Sloan Kettering Cancer Center | Not a company | Analytical validation | 1 | May 19, 2017 |
Showing 5 of 23 assay-provider companies.
Actionable biomarkers (6)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| JAK2-BRAF fusion | Ruxolitinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| JAK2 (V617F) | Ruxolitinib | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| JAK2 (V617F) | Jak Inhibitor (alone Or In Combination)s | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| JAK2 amplification | Jak Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| JAK2 oncogenic mutation | Pd1 Inhibitors | responsive | cutaneous melanoma | Cancer Genome Interpreter |
Showing 5 of 6 actionable-biomarker assertions.
Trial mentions (182)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT07249840 | Trial eligibility (AACT) |
| NCT00940784 | Trial eligibility (AACT) |
| NCT02598297 | Trial eligibility (AACT) |
| NCT02055781 | Trial eligibility (AACT) |
Showing 5 of 182 trial mentions.
Target-disease associations (1,228)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-methylglutaconic aciduria, type VIIA | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Aarskog-Scott syndrome, X-linked | genetic, familial or congenital disease | Literature (Europe PMC) |
| Abdominal obesity | nutritional or metabolic disease | Literature (Europe PMC) |
| Abnormal erythrocyte morphology | phenotype | GWAS credible sets |
| Abnormal male internal genitalia morphology | phenotype | GWAS credible sets |
Showing 5 of 1,228 associations.
Vendor sourcing (581)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Missens... | View ClinVar record SCV005905499.1 |
| AOP Orphan (Austria) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Willing and able to give written informed consent prior to any study specific procedures and able to comply with this protocol 2. Male or female subjec... | View trial NCT01230775 |
| AOP Orphan (Austria) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Written informed consent obtained prior to any study specific screening activities and able to comply with this protocol. 2. Patients age ≥18 years 3. ... | View trial NCT01193699 |
| AOP Orphan (Austria) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patients who either completed the 12 months AOP2014 treatment arm of the PROUD-PV study, or are currently participating in the CONTINUATION-PV, and at ... | View trial NCT02523638 |
| AOP Orphan (Austria) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patients who completed the 12 months AOP2014 treatment arm of the PROUD-PV study and at the "end-of-treatment visit" (EoT) of the PROUD-PV study who fu... | View trial NCT02218047 |
Showing 5 of 581 sourcing records.
Trial-cited literature (1,187)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. | Blood neoplasia | 2026 | 0 |
| Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women. | Journal of the American College of Cardiology | 2025 | 18 |
| Non-invasive vagus nerve stimulation and exercise capacity in healthy volunteers: a randomized trial. | European heart journal | 2025 | 13 |
| Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. | American journal of clinical dermatology | 2025 | 13 |
Showing 5 of 1,187 papers.
Protein variant mentions (24)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D1096E | 1 | 2015 | PMID 25741868 |
| p.D146N | 1 | 2015 | PMID 25741868 |
| p.E1490X | 1 | 2009 | PMID 19295549 |
| p.E627A | 1 | 2018 | PMID 30304655 |
| p.E846D | 1 | 2015 | PMID 25741868 |
Showing 5 of 24 variants.
Literature-extracted relations (352)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Lipopolysaccharides | Chemical | associate |
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-<i>κ</i>B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways. | 2021 |
| Oxygen | Chemical | associate |
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. | 2021 |
| Folic (or folinic) acid | Chemical | associate |
Differential responses to folic acid in an established keloid fibroblast cell line are mediated by JAK1/2 and STAT3. | 2021 |
| Silybin | Chemical | negative_correlate |
Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. | 2020 |
| HYDROXYUREA | Chemical | negative_correlate |
Cardiovascular events and intensity of treatment in polycythemia vera. | 2013 |
Showing 5 of 352 relation assertions.
Organizations publishing (732)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mayo Clinic | Hospital | 54 | 2007 to 2025 |
| The University of Texas System | Academic | 49 | 2009 to 2026 |
| University of Florence | Academic | 45 | 2013 to 2026 |
| Memorial Sloan Kettering Cancer Center | Hospital | 42 | 2010 to 2025 |
| Government of the United States of America | Government | 37 | 1999 to 2024 |
Showing 5 of 732 organizations.
Where JAK2 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
1,013 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.